Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031077172> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W3031077172 endingPage "2921" @default.
- W3031077172 startingPage "2919" @default.
- W3031077172 abstract "Objective To study the clinical curative effect of adefovir and lamivudine in the treatment of chronic hepatitis B .Methods 68 patients with chronic hepatitis B were randomly divided into the treatment group and control group,34 cases in each group.The treatment group was treated with adefovir and lamivudine for 48 weeks,the control group was treated by lamivudine for 48 weeks.12,24,36,48 weeks after treatment ,the changes of liver func-tion,ALT index in HBV DNA,HBV DNA and the changes of serum HBeAg negative rate ,HBeAg/HBeAb seroconver-sion rate and adverse reaction were observed and compared .Results With the extension of treatment time ,ALT,HBV DNA in the two groups were gradually decreased , there were significant differences before and after treatment （ t=4.63,4.65,P〈0.05）.24,36,48 weeks after treatment,ALT,HBV DNA in the treatment group were significantly lower than those in the control group[ALT （89.9 ±16.7） U/L,（60.1 ±13.8） U/L,（44.6 ±8.9） U/L vs （90.7 ± 17.6） U/L,（72.0 ±14.1） U/L,（61.3 ±24.5） U/L;HBV DNA （4.92 ±1.44） U/L,（3.35 ±1.37） U/L,（2.53 ± 1.31） U/L vs （5.02 ±1.41） U/L,（3.69 ±1.40） U/L,（3.02 ±1.35） U/L],there were significant differences between two groups（F=4.32,4.56.4.76,all P〈0.05）.After treatment,the HBV DNA and HBeAg negative con-version rate,HBeAg/HBeAb seroconversion rate in two groups were increased significantly ,the differences were statis-tically significant（χ2 =4.63,4.36,4.21,4.27,4,35,4.23,all P〈0.05）.At the 24th week of treatment,the serolog-ical markers of HBV had no significant difference , but after 24 weeks, serum markers in the treatment group （67.65%,32.35%,26.47%,85.29%,38.23%,35.29%） were obviously higher than those in the control group , the differences between the two groups were significant （χ2 =4.43,4.73,4.23,4.32,4.34,4.46,4.76,4.34,4.22, 4.29,4.34,4.45,all P〈0.05）.Conclusion Adefovir and lamivudine combination therapy in the treatment of chro-nic hepatitis B has obvious clinical effect ,has no serious adverse reactions ,which is suitable for clinical application .Key words: Adefovir dipivoxil; Lamivudine; Hepatitis B,chronic" @default.
- W3031077172 created "2020-06-05" @default.
- W3031077172 creator A5055294541 @default.
- W3031077172 creator A5064162441 @default.
- W3031077172 creator A5075654157 @default.
- W3031077172 date "2014-10-01" @default.
- W3031077172 modified "2023-09-25" @default.
- W3031077172 title "Clinical efficacy of adefovir and lamivudine in the treatment of chronic hepatitis B" @default.
- W3031077172 doi "https://doi.org/10.3760/cma.j.issn.1008-6706.2014.19.014" @default.
- W3031077172 hasPublicationYear "2014" @default.
- W3031077172 type Work @default.
- W3031077172 sameAs 3031077172 @default.
- W3031077172 citedByCount "0" @default.
- W3031077172 crossrefType "journal-article" @default.
- W3031077172 hasAuthorship W3031077172A5055294541 @default.
- W3031077172 hasAuthorship W3031077172A5064162441 @default.
- W3031077172 hasAuthorship W3031077172A5075654157 @default.
- W3031077172 hasConcept C126322002 @default.
- W3031077172 hasConcept C159047783 @default.
- W3031077172 hasConcept C2522874641 @default.
- W3031077172 hasConcept C2775940106 @default.
- W3031077172 hasConcept C2777382497 @default.
- W3031077172 hasConcept C2777410769 @default.
- W3031077172 hasConcept C2777869810 @default.
- W3031077172 hasConcept C2779517838 @default.
- W3031077172 hasConcept C2780593183 @default.
- W3031077172 hasConcept C3020491458 @default.
- W3031077172 hasConcept C71924100 @default.
- W3031077172 hasConcept C90924648 @default.
- W3031077172 hasConceptScore W3031077172C126322002 @default.
- W3031077172 hasConceptScore W3031077172C159047783 @default.
- W3031077172 hasConceptScore W3031077172C2522874641 @default.
- W3031077172 hasConceptScore W3031077172C2775940106 @default.
- W3031077172 hasConceptScore W3031077172C2777382497 @default.
- W3031077172 hasConceptScore W3031077172C2777410769 @default.
- W3031077172 hasConceptScore W3031077172C2777869810 @default.
- W3031077172 hasConceptScore W3031077172C2779517838 @default.
- W3031077172 hasConceptScore W3031077172C2780593183 @default.
- W3031077172 hasConceptScore W3031077172C3020491458 @default.
- W3031077172 hasConceptScore W3031077172C71924100 @default.
- W3031077172 hasConceptScore W3031077172C90924648 @default.
- W3031077172 hasIssue "19" @default.
- W3031077172 hasLocation W30310771721 @default.
- W3031077172 hasOpenAccess W3031077172 @default.
- W3031077172 hasPrimaryLocation W30310771721 @default.
- W3031077172 hasRelatedWork W2348927682 @default.
- W3031077172 hasRelatedWork W2349642934 @default.
- W3031077172 hasRelatedWork W2350310509 @default.
- W3031077172 hasRelatedWork W2350787707 @default.
- W3031077172 hasRelatedWork W2351722123 @default.
- W3031077172 hasRelatedWork W2352652324 @default.
- W3031077172 hasRelatedWork W2363757513 @default.
- W3031077172 hasRelatedWork W2365416088 @default.
- W3031077172 hasRelatedWork W2366294606 @default.
- W3031077172 hasRelatedWork W2372670347 @default.
- W3031077172 hasRelatedWork W2375807400 @default.
- W3031077172 hasRelatedWork W2376137666 @default.
- W3031077172 hasRelatedWork W2377996872 @default.
- W3031077172 hasRelatedWork W2378029090 @default.
- W3031077172 hasRelatedWork W2389369260 @default.
- W3031077172 hasRelatedWork W2392879822 @default.
- W3031077172 hasRelatedWork W292574809 @default.
- W3031077172 hasRelatedWork W3029479021 @default.
- W3031077172 hasRelatedWork W3030932756 @default.
- W3031077172 hasRelatedWork W3031594548 @default.
- W3031077172 hasVolume "21" @default.
- W3031077172 isParatext "false" @default.
- W3031077172 isRetracted "false" @default.
- W3031077172 magId "3031077172" @default.
- W3031077172 workType "article" @default.